About GlaxoSmithKline plc
GlaxoSmithKline plc -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information including a copy of this announcement and details of the company's updated product development pipeline, visit GSK at http://www.gsk.com.
Sirtris Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with ageing, including metabolic diseases such as Type 2 Diabetes. Sirtris's drug candidates are designed to mimic certain beneficial health effects of calorie restriction by activation of sirtuins, a recently discovered class of enzymes that Sirtris believes control the ageing process. The company's headquarters are in Cambridge, Massachusetts.
Cautionary statement regarding forward-looking statements
Under the safe harbour provisions of the US Private Securities
Litigation Reform Act of 1995, investors are cautioned that any
forward-looking statements or projections made by GSK, including those made
in this press release, are subject to risks and uncertainties that may
cause actual results or events to differ materially from those projected or
anticipated. These statements are based on GSK's current expectations and
beliefs. Actual results or events could differ materially from the results
or anticipated events implied by these statements. Factors that may cause
or contribute to such differences include the risk that the conditions to
the closing of the tender offer or the merger set forth in the merger
agreement will not be satisfied;
|SOURCE GlaxoSmithKline plc|
Copyright©2008 PR Newswire.
All rights reserved